Revvity’s shares (currently trading at $111) have posted a disappointing 8.5% loss, well below the S&P 500’s 5.1% gain. This ...

Discover how Revvity's strategic acquisitions and financial improvements position it for long-term growth in cell and gene ...

Revvity expects 2025 revenue to be in the range ... rose 4% to $393.2 million. Formerly known as PerkinElmer, the company divested three of its businesses in 2022 to focus on life sciences and ...

Formerly known as PerkinElmer, Revvity (NYSE:RVTY) offers advanced diagnostic tools, scientific instruments, and services designed to support the pharmaceutical and biotechnology industries.

Revvity (RVTY) announced that the Massachusetts Superior Court has ruled in its favor and will issue a permanent injunction to enforce ...

“Revvity, Inc. (NYSE:RVTY)—the former PerkinElmer—has been on a roller coaster ride the last few years. It generated windfall prohts from its testing business during Covid, disposed of its ...

Try Now>> See today’s best-performing stocks on TipRanks >> Read More on RVTY: PerkinElmer NewsMORE Related Stocks Indices Commodities Currencies Stocks ...

In the last three months, 7 analysts have published ratings on Revvity (NYSE:RVTY), offering a diverse range of perspectives from bullish to bearish. The table below offers a condensed view of ...

WALTHAM, Mass.--(BUSINESS WIRE)-- Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences in March 2025: 46th Annual Raymond James Institutional Investor ...

WALTHAM, Mass. (AP) — WALTHAM, Mass. (AP) — Revvity, Inc. (RVTY) on Friday reported fourth-quarter net income of $94.6 million. The Waltham, Massachusetts-based company said it had net income ...

WALTHAM, Mass. & SAN DIEGO--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced a strategic agreement to commercialize an in vitro diagnostic (IVD) workflow solution for neonatal ...